Effects of apolipoprotein E-ε4 and -ε2 in amnestic mild cognitive impairment and dementia in Shanghai: SCOBHI-P

American Journal of Alzheimer's Disease and other Dementias

Volumn 25, Issue 3, 2010, Pages 233-238

  Borenstein, Amy R ^a   Mortimer, James A ^a   Ding, Ding ^b   Schellenberg, Gerard D ^c   Decarli, Charles ^d   Zhao, Qianhua ^b   Copenhaver, Cathleen ^a   Guo, Qihao ^b   Chu, Shugang ^b   Galasko, Douglas ^e   Salmon, David P ^e   Qi, Dai ^f   Wu, Yougui ^a   Petersen, Ronald ^g   Hong, Zhen ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g MAYO CLINIC   (United States)

Author keywords

Apolipoprotein E; China; Dementia; Mild cognitive impairment

Indexed keywords

APOLIPOPROTEIN E EPSILON2; APOLIPOPROTEIN E EPSILON4; APOLIPOPROTEIN E2; UNCLASSIFIED DRUG;

AGED; ARTICLE; CHINA; CONTROLLED STUDY; DEMENTIA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; RISK ASSESSMENT;

EID: 77952131539     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317509357736     Document Type: Article

References (60)

1. Mak YT, Chiu H., Woo J., et al. Apolipoprotein E genotype and Alzheimers disease in Hong Kong elderly Chinese. Neurology. 1996 ; 46 (1). 146-149.
2. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta-Analysis Consortium. JAMA. 1997 ; 278 (16). 1349-1356.
3. Katzman R., Zhang MY, Chen PJ, et al. Effects of apolipoprotein E on dementia and aging in the Shanghai Survey of Dementia. Neurology. 1997 ; 49 (3). 779-785.
4. Zhang JG, Yang JG, Lin X., et al. Apolipoprotein E ε4 allele is a risk factor for late-onset Alzheimers disease and vascular dementia in Han Chinese. Int J Geriatr Psychiatry. 2001 ; 16 (4). 436-441.
5. Bennett DA, Wilson RS, Schneider JS, et al. Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimers disease. Neurology. 2003 ; 60 (2). 246-252.
6. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimers disease in late-onset families. Science. 1993 ; 261 (5123). 921-923.
7. Murrell JR, Price B., Lane KA, et al. Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Arch Neurol. 2006 ; 63 (3). 431-434.
8. Borenstein A., Mortimer JA, Wu Y., et al. Apolipoprotein E and cognition in population-based samples of African Americans and Whites. Ethnicity and Disease. 2006 ; 16 (1). 9-15.
9. Wilson RS, Bienias JL, Berry-Kravis E., Evans DA, Bennett DA The apolipoprotein E epsilon 2 allele and decline in episodic memory. J Neurol Neurosurg Psych. 2002 ; 73 (6). 672-677.
10. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Gen. 1994 ; 7 (2). 180-184.
11. Lung FW, Yen YC, Chou LJ, Hong CJ, Wu CK The allele interaction between apolipoprotein ε2 and ε4 in Taiwanese Alzheimers disease patients. Acta Psychiatr Scand. 2005 ; 111 (1). 38-43.
12. Davignon J., Gregg RE, Sing CF Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988 ; 8 (1). 1-21.
13. Chen HH, Hu CJ The genetic studies of dementias in Taiwan. Acta Neurol Taiwan. 2006 ; 15 (1). 60-63.
14. Lai CL, Tai CT, Lin SR, Lin RT, Yang YH, Liu CK. Apolipoprotein E in Taiwan Chinese patients with dementia. Dement Geriatr Cogn Disord. 2003 ; 16 (4). 208-211.
15. Petersen RC Mild Cognitive Impairment: Aging to Alzheimers disease. New York, NY: Oxford University Press ; 2003 :238.
16. Reiman EM, Chen K., Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimers dementia. Proc Natl Acad Sci. 2004 ; 101 (1). 284-289.
17. Okello A., Koivunen J., Edison P., et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009 ; 73 (10). 744-745.
18. Yaffe K., Petersen RC, Lindquist K., Kramer J., Miller B. Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord. 2006 ; 22 (4). 312-319.
19. Teng EL, Hasegawa K., Homma A., et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiologic studies of dementia. Int Psychogeriatr. 1994 ; 6 (1). 45-56.
20. Wechsler D. WAIS-R Manual: Wechsler Adult Intelligence Scale-Revised. New York, NY: Psychological Corporation ; 1981.
21. Gauthier L., Dehaut F., Joanette Y. The Bells test: a quantitative and qualitative test for visual neglect. Int J Clin Neuropsychol. 1989 ; 11 (2). 49-54.
22. Wechsler D. Wechsler Memory Scale-Revised Manual. San Antonio: Psychological Corporation ; 1987.
23. Rey A. L-examen psychologique dans les cas dencephalopathie traumatique. Arch Psychologie. 1941 ; 28: 286-340.
24. Golden CJ Stroop Color and Word Test. Chicago, IL: Stoelting Company ; 1978.
25. Schmidt M. Rey Auditory Verbal Learning Test. A Handbook. Los Angeles, CA: Western Psychological Services ; 1996.
26. Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Motor Skills. 1958 ; 8: 271-276.
27. Rouleau I., Salmon DP, Butters N., Kennedy C., McGuire K. Quantitative and qualitative analyses of clock drawings in Alzheimers and Huntingtons disease. Brain Cogn. 1992 ; 18 (1). 70-87.
28. Kaplan EF, Goodglass H., Weintraub S. The Boston Naming Test. Philadelphia, PA: Lea & Fibiger ; 1983.
29. Mattis S. Dementia Rating Scale (DRS). Odessa, FL: Psychological Assessment Resources ; 1988.
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4 th ed. Washington DC: APA ; 2000.
31. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EM Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology. 1984 ; 34 (7). 939-944.
32. Roèn GC, Tatemichi TK, Erkinjuntti T., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993 ; 43 (2). 250-260.
33. Petersen RC, Doody R., Kurz A., et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001 ; 58 (12). 1985-1992.
34. Petersen RC Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004 ; 256 (3). 183-194.
35. Guo Q., Lu CZ, Hong Z. Reliability and validity of auditory verbal learning test on Chinese elderly patients. Chinese Mental Health J. 2001 ; 15 (1). 13-15.
36. Guo Q., Sun YM, Yu PM, Hong Z., Lu CZ Norms for Auditory Verbal Learning Test in the normal aged in Chinese community. Chinese J Clin Psychol. 2007 ; 15 (2). 132-135.
37. Emi M., Wu LL, Robertson MA, et al. Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics. 1988 ; 3 (4). 373-379.
38. Hixson JE, Vernier DT Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J. Lipid Res. 1990 ; 31: 545-548.
39. SAS Institute. SAS System for Microsoft Windows (version 9). Cary, NC: SAS Institute Inc ; 2003.
40. Bertram L., Lill CM, McQueen MB, Schieide BMM, Zauft U. Alzgene: Published AD candidate genes. www.alzgene.org/meta.asp?geneID=83. Alzheimer Research Forum, www.alzforum.org, 2009. Accessed August 17, 2009.
41. Wang QS, Tian L., Huang YL, Qin S., He LQ, Zhou JN Olfactory identification and apolipoprotein E ε4 allele in mild cognitive impairment. Brain Res. 2002 ; 951 (1). 77-81.
42. Lehtovirta M., Helisalmi S., Mannermaa A., et al. Apolipoprotein E polymorphism and Alzheimers disease in Eastern Finland. Neurosci Lett. 1995 ; 185 (1). 13-15.
43. Chartier-Harlin MC, Parfitt M., Legrain S., et al. Apolipoprotein E ε4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimers disease: analysis of the 19q132 chromosomal region. Hum Mol Gen. 1994 ; 3 (4). 569-574.
44. Ehnholm C., Lukka M., Kuusi T., Nlkklla E., Utermann Q. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res. 1986 ; 27 (3). 227-235.
45. Tsai MS, Tangalos EG, Petersen RC, et al. Apolipoprotein E: risk factor for Alzheimer Disease. Am J Hum Gen. 1994 ; 54 (4). 643-649.
46. Kukull WA, Schellenberg GD, Bowen JD, et al. Apolipoprotein E in Alzheimers Disease risk and case detection: a case-control study. J Clin Epidemiol. 1996 ; 49 (10). 1143-1148.
47. Rebeck GW, Kindy M., LaDu MJ Apolipoprotein E and Alzheimers disease: the protective effects of ApoE2 and E3. Journal of Alzheimers Disease. 2002 ; 4 (3). 145-154.
48. Mortimer JA, Snowdon DA, Markesbery WR The effect of APOE-ε4 on dementia is mediated by Alzheimer neuropathology. Alzheimer Dis Assoc Disord. 2009 ; 23 (2). 152-157.
49. Wu YN, Zhang JW, Zhang ZX, Qu QM, Chen D. An association analysis of apolipoprotein E genotypes with Alzheimers disease in Chinese population. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2001 ; 23 (5). 450-454.
50. Huang HM, Kuo YM, Ou HC, Lin CC, Chuo LJ. Apolipoprotein E polymorphism in various dementias in Taiwan Chinese population. Journal of Neur Transm. 2002 ; 109 (11). 1415-1421.
51. Lam LC, Tang NL, Ma SL, et al. Apolipoprotein episolon-4 allele and the two-year progression of cognitive function in Chinese subjects with late-onset Alzheimers disease. Am J Alzheimers Dis Other Demen. 2006 ; 21 (2). 92-99.
52. Liu HC, Hong CJ, Wang SJ, et al. ApoE genotype in relation to AD and cholesterol: a study of 2,326 Chinese adults. Neurology. 1999 ; 53 (5). 962-966.
53. Qiu C., Kivipelto M., Agüero-Torres H., Winblad B., Fratiglioni L. Risk and protective effects of the APOE gene towards Alzheimers disease in the Kungsholmen project: variation by age and sex. J Neurol Neurosurg Psych. 2004 ; 75 (6). 828-833.
54. Berlau DJ, Corrada MM, Head E., Kawas CH APOE ε2 is associated with intact cognition by increased Alzheimer pathology in the oldest old. Neurology. 2009 ; 72 (9). 829-834.
55. Poirier J. Apolipoprotein E. represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimers disease. Alzheimers Dementia. 2008 ; 4 (1). S91 - S97.
56. Holtzman DM In vivo effects of ApoE and clusterin on amyloid2 metabolism and neuropathology. J Mol Neurosci. 2004 ; 23 (3). 247-254.
57. Greenberg SM, Rebeck GW, Vonsattel JPG, Gomez-Isla T., Hyman BT Apolipoprotein E e4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995 ; 38 (2). 254-259.
58. Strittmatter WJ, Roses AD Apolipoprotein E and Alzheimers disease. Annu Rev Neurosci. 1996 ; 19: 53-57.
59. Lahoz C., Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis. 2001 ; 154 (3). 529-537.
60. Wang PN, Lirng JF, Lin KN, Chang FC, Liu HC Prediction of Alzheimers disease in mild cognitive impairment: a prospective study in Taiwan. Neurobio Aging. 2006 ; 27 (12). 1797-1806.